Table 1 Demographic characteristics of the study population
|  | Total study population (n = 964) | Olanzapine (n = 241) | Risperidone (n = 241) | Amisulpride (n = 241) | Aripiprazole (n = 241) |
|---|---|---|---|---|---|
Age (year) | 27.89 ± 8.59 | 28.10 ± 9.79 | 28.27 ± 8.69 | 26.94 ± 7.49 | 28.26 ± 7.49 |
Sex (male/female) | 448/518 | 116/125 | 100/141 | 124/117 | 108/133 |
Duration (month) | 24.81 ± 19.70 | 23.19 ± 15.37 | 24.57 ± 18.35 | 26.18 ± 20.59 | 25.31 ± 23.56 |
PANSS total score | 84.52 ± 19.20 | 85.56 ± 13.75 | 83.69 ± 13.43 | 85.03 ± 13.75 | 83.80 ± 15.96 |
Dose of antipsychotic (mg/day) |  | 17.17 ± 4.81 | 4.55 ± 1.39 | 634.85 ± 198.19 | 20.44 ± 6.34 |
Severity of illness | |||||
 Severe schizophrenia (PANSS total score > 95) | 190 | 49 | 42 | 54 | 45 |
 Moderate schizophrenia (95 ≥ PANSS total score > 75) | 521 | 133 | 132 | 132 | 124 |
 Mild schizophrenia (75 ≥ PANSS total score > 58) | 253 | 59 | 67 | 55 | 72 |